Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5113-5121

  Garcia Rivera, Jose A ^a   Bobardt, Michael ^a   Chatterji, Udayan ^a   Hopkins, Sam ^b   Gregory, Matthew A ^c   Wilkinson, Barrie ^c   Lin, Kai ^d   Gallay, Philippe A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCYNEXIS Inc   (United States)

^c BIOTICA TECHNOLOGY LTD   (United Kingdom)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; CYCLOPHILIN A; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; HEPATITIS C VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CYCLOSPORINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84866309587     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00919-12     Document Type: Article

References (58)

1. Ahn J, et al. 2004. Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. J. Biochem. Mol. Biol. 37:741-748. (Pubitemid 40221537)
2. Alter MJ. 2007. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13:2436-2441. (Pubitemid 46929498)
3. Armstrong GL, et al. 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144:705-714. (Pubitemid 46780630)
4. Chatterji U, et al. 2009. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 284:16998-17005.
5. Chatterji U, et al. 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 53:50-56.
6. Coelmont L, et al. 2010. DEB025 (alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One 5:e13687. doi:10.1371/journal.pone.0013687.
7. Combet C, Blanchet C, Geourjon C, Deleage G. 2000. NPS@: network protein sequence analysis. Trends Biochem. Sci. 25:147-150. (Pubitemid 30122428)
8. Cross TJ, Antoniades CG, Harrison PM. 2008. Current and future management of chronic hepatitis C infection. Postgrad. Med. J. 84:172-176. (Pubitemid 351600788)
9. Dienstag JL, McHutchison JG. 2006. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130:214-264.
10. Fernandes F, Ansari IU, Striker R. 2010. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One 5:e9815. doi:10.1371/journal.pone.0009815.
11. Fernandes F, et al. 2007. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 46:1026-1033. (Pubitemid 350144767)
12. Fischer G, Gallay P, Hopkins S. 2010. Cyclophilin inhibitors for the treatment of HCV infection. Curr. Opin. Investig. Drugs 11:911-918.
13. Flisiak R, et al. 2008. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47:817-826. (Pubitemid 351449673)
14. Foster TL, Gallay P, Stonehouse NJ, Harris M. 2011. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. Virol. 85:7460-7464.
15. Gaither LA, et al. 2010. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology 397:43-55.
16. Gallay PA. 2011. Cyclophilin inhibitors: a novel class of promising hosttargeting anti-HCV agents. Immunol. Res. 52:200-210.
17. Goto K, Watashi K, Inoue D, Hijikata M, Shimotohno K. 2009. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci. 100:1943-1950.
18. Goto K, et al. 2006. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun. 343:879-884.
19. Gregory MA, et al. 2011. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrob. Agents Chemother. 55:1975-1981.
20. Grise H, Frausto S, Logan T, Tang H. 2012. A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates alisporivir susceptibility. J. Virol. 86:4811-4822.
21. Hanoulle X, Badillo A, Verdegem D, Penin F, Lippens G. 2010. The domain 2 of the HCV NS5A protein is intrinsically unstructured. Protein Peptide Lett. 17:1012-1018.
22. Hanoulle X, et al. 2009. Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J. Biol. Chem. 284:13589-13601.
23. He Y, Staschke KA, Tan SL. 2006. HCV NS5A: a multifunctional regulator of cellular pathways and virus replication. In Tan SL (ed), HepatitisC viruses: genomes and molecular biology. Horizon Bioscience, Norfolk, United Kingdom.
24. Hopkins S, et al. 2012. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. 57:47-54.
25. Hopkins S, et al. 2010. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 54:660-672.
26. Ishii N, et al. 2006. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. 80:4510-4520.
27. Jones DM, Gretton SN, McLauchlan J, Targett-Adams P. 2007. Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA. J. Gen. Virol. 88:470-475. (Pubitemid 46210885)
28. Kaul A, et al. 2009. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 5:e1000546. doi:10.1371/journal.ppat.1000546.
29. Lawitz E, et al. 2011. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res. 89:238-245.
30. Lemm JA, et al. 2011. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrob. Agents Chemother. 55:3795-3802.
31. Lin K. 2010. Development of novel antiviral therapies for hepatitis C virus. Virol. Sinica 25:246-266.
32. Liu Z, Yang F, Robotham JM, Tang H. 2009. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol. 83:6554-6565.
33. Ma S, et al. 2006. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob. Agents Chemother. 50:2976-2982. (Pubitemid 44396401)
34. Macdonald A, Harris M. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85:2485-2502. (Pubitemid 39214345)
35. Manns MP, Wedemeyer H, Cornberg M. 2006. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350-1359. (Pubitemid 44277369)
36. Moradpour D, et al. 2004. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol. 78:7400-7409. (Pubitemid 38915885)
37. Nakagawa M, et al. 2004. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. 313:42-47. (Pubitemid 37524022)
38. Nakagawa M, et al. 2005. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 129:1031-1041. (Pubitemid 41242693)
39. Paeshuyse J, et al. 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43:761-770.
40. Pawlotsky JM. 2012. New antiviral agents for hepatitis C. F1000 Biol. Rep. 4:5. doi:10.3410/B4-5.
41. Pockros PJ. 2010. New direct-acting antivirals in the development for hepatitis C virus infection. Therap. Adv. Gastroenterol. 3:191-202.
42. Puyang X, et al. 2010. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob. Agents Chemother. 54:1981-1987.
43. Reiss S, et al. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45.
44. Robida JM, Nelson HB, Liu Z, Tang H. 2007. Characterization of hepatitisCvirus subgenomic replicon resistance to cyclosporine in vitro. J. Virol. 81:5829-5840. (Pubitemid 46847020)
45. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5:558-567. (Pubitemid 41196755)
46. Shirota Y, et al. 2002. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J. Biol. Chem. 277:11149-11155. (Pubitemid 34952876)
47. Simmonds P, et al. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973. (Pubitemid 41401136)
48. Soriano V, et al. 2008. Emerging drugs for hepatitis C. Expert Opin. Emerg. Drugs 13:1-19. (Pubitemid 351448700)
49. Sy T, Jamal MM. 2006. Epidemiology of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 3:41-46.
50. Tellinghuisen TL, Marcotrigiano J, Rice CM. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-379. (Pubitemid 40745549)
51. Tong MJ, et al. 1997. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 26:747-754. (Pubitemid 27392369)
52. Vermehren J, Sarrazin C. 2011. New hepatitis C therapies in clinical development. Eur. J. Med. Res. 16:303-314.
53. von Hahn T, Ciesek S, Manns MP. 2011. Arrest all accessories-inhibition of hepatitis C virus by compounds that target host factors. Discov. Med. 12:237-244.
54. Waller H, Chatterji U, Gallay P, Parkinson T, Targett-Adams P. 2010. The use of AlphaLISA technology to detect interaction between hepatitisC virus-encoded NS5A and cyclophilin A. J. Virol. Methods 165:202-210.
55. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282-1288. (Pubitemid 37314838)
56. WHO. 1999. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepatitis 6:35-47.
57. Yang F, et al. 2010. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog. 6:e1001118. doi:10.1371/journal.ppat.1001118.
58. Zhang C, et al. 2005. Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase. J. Virol. 79:8687-8697. (Pubitemid 40934779)